Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

NAUT
Nautilus Biotechnolgy, Inc. Common Stock
stock NASDAQ

At Close
May 12, 2025 3:59:30 PM EDT
0.7310USD+4.429%(+0.0310)141,863
0.00Bid   0.00Ask   0.0000Spread
Pre-market
Dec 31, 1969 7:00:00 PM EST
0.00USD-100.000%(-0.70)0
After-hours
May 8, 2025 4:15:30 PM EDT
0.7100USD-2.204%(-0.0160)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
08:00AM EST  Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome,today announced it will report financial results for the fourth quarter and full year 2021 before market open on Thursday, February 24th, 2022.   GlobeNewswire Inc
Jan 6, 2022
10:06AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022   Benzinga
05:57AM EST  Morgan Stanley Initiates Coverage On Nautilus Biotechnology with Equal-Weight Rating, Announces Price Target of $8   Benzinga
Dec 10, 2021
04:13PM EST  Nautilus Biotechnology Reports Form4 Filing Director Joseph Edelman Buys 200K Shares At Average Price Of $5.36/Share   Benzinga
Nov 2, 2021
11:11AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2021   Benzinga
10:56AM EDT  Nautilus Biotechnology And Abcam Announce Supply Agreement For Abcam To Provide Nautilus With Antibodies; Financial Terms Not Disclosed   Benzinga
10:56AM EDT  Nautilus, Abcam Announce Strategic Partnership To Accelerate Exploration Of Proteome; Terms Not Disclosed   Benzinga
10:49AM EDT  Cowen & Co. Initiates Coverage On Nautilus Biotechnology with Outperform Rating   Benzinga
10:44AM EDT  Nautilus Biotechnology Q3 EPS $(0.12) Misses $(0.10) Estimate   Benzinga
10:41AM EDT  Earnings Scheduled For November 2, 2021   Benzinga
08:03AM EDT  Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of   PR Newswire
08:02AM EDT  Nautilus And Abcam Announce Strategic Development And Supply Partnership   RTTNews
08:00AM EDT  Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam(AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, today announced a strategic development and supply partnership.   GlobeNewswire Inc
06:00AM EDT  Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today reported financial results for the third quarter ended September30, 2021.   GlobeNewswire Inc
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 11, 2021
08:00AM EDT  Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome,today announced it will report financial results for the third quarter of fiscal year 2021 before market open on Tuesday, November 2nd, 2021.   GlobeNewswire Inc
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Oct 1, 2021
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 30, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug   Benzinga
Sep 29, 2021
08:13AM EDT  The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug   Benzinga
Sep 28, 2021
08:18AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive   Benzinga
08:16AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments   Benzinga
Sep 16, 2021
07:48AM EDT  The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study   Benzinga
Sep 14, 2021
07:50AM EDT  The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout   Benzinga
Sep 3, 2021
09:00AM EDT  Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome,today announced the company will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference.   GlobeNewswire Inc
Aug 19, 2021
03:23PM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2021   Benzinga
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 10, 2021
06:16AM EDT  Nautilus Biotechnology Q2 EPS $(0.19) Misses $(0.09) Estimate   Benzinga
06:00AM EDT  Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome, today reported financial results for the second quarter ended June30, 2021.   GlobeNewswire Inc
04:05AM EDT  Earnings Scheduled For August 10, 2021   Benzinga
Aug 9, 2021
08:00AM EDT  Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development. He and his team will work out of Nautilus research headquarters in San Carlos, California.   GlobeNewswire Inc
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 4, 2021
10:34AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2021   Benzinga
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
05:02AM EDT  Goldman Sachs Initiates Coverage On Nautilus Biotechnology with Neutral Rating, Announces Price Target of $10   Benzinga
Aug 3, 2021
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
Jul 29, 2021
08:18AM EDT  The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 22, 2021
11:34AM EDT  The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO   Benzinga
Jul 13, 2021
10:13AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021   Benzinga
08:00AM EDT  Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome,today announced it will report financial results for the second quarter of fiscal year 2021 before market open on Tuesday, August 10th, 2021.   GlobeNewswire Inc
06:31AM EDT  Jefferies Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $13   Benzinga
Jun 17, 2021
07:06AM EDT  Nautilus Biotechnology Appoints Emma Lundberg To Scientific Advisory Board   RTTNews
07:00AM EDT  Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Emma Lundberg, Ph.D. to its Scientific Advisory Board (SAB), effective today.   GlobeNewswire Inc
Jun 15, 2021
08:07AM EDT  The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda   Benzinga
Jun 13, 2021
03:13PM EDT  Last Week's Notable Insider Buys: Lululemon Athletica, Opendoor Technologies And More   Benzinga
Jun 9, 2021
10:05PM EDT  Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC